Gary Thomas is a Neurology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
500 University Dr
Hershey, PA 170332360
Telephone
800-233-4082Registry record last updated 22 Jan 2010.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- Celgene CorporationProgram year20241 payment
- TG THERAPEUTICS, INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
44.8%Potassium Channel Blocker10.4%Dalfampridine Er100%Part D≥27 patientsGabapentinoids9.3%Gabapentin86%Pregabalin15%Part D<11 patients+ 14 more classes in this area
Cancer & immunology
32.9%Other immunostimulants11.7%Copaxone74%Glatiramer Acetate16%Glatopa11%Part D<11 patientsOther immunosuppressants9.6%Vumerity44%Dimethyl Fumarate35%Tecfidera22%Part D<11 patients+ 3 more classes in this area
Musculoskeletal
15%gamma-Aminobutyric Acid-ergic Agonist13.4%Baclofen100%Part D≥51 patientsCentral alpha-2 Adrenergic Agonist1.6%Tizanidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Molecular, Cellular and Behavioral Impact of the R203W PACS1 Syndrome Mutation
University of Pittsburgh at Pittsburgh
FY2026$654,896R01NS123649 - Impact of the E209K PACS2 Syndrome mutation on neuronal metabolism and neurotransmission.
University of Pittsburgh at Pittsburgh
FY2026$601,401R01NS136370 - Molecular, Cellular and Behavioral Impact of the R203W PACS1 Syndrome Mutation
University of Pittsburgh at Pittsburgh
FY2025$654,896R01NS123649
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”